Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

Pharmaceuticals

Dalia Ricci¹  Valentina Tateo¹  Mariacristina Di Marco¹  Riccardo Carloni¹  Giovanni Brandi¹  Alessandro Di Federico¹  Andrea Palloni¹  Claudia Parisi¹  Giorgio Frega¹  Alessandro Rizzo¹  Francesca Formica¹ 

[1] Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy;

关键词: pancreatic cancer;    immunotherapy;    targeted therapy;    tyrosine kinase inhibitor;    personalized medicine;    metabolism;   

DOI  :  10.3390/ph14070677

来源: DOAJ

【 摘 要 】

Pancreatic cancer (PC) is a recalcitrant disease characterized by high incidence and poor prognosis. The extremely complex genomic landscape of PC has a deep influence on cultivating a tumor microenvironment, resulting in the promotion of tumor growth, drug resistance, and immune escape mechanisms. Despite outstanding progress in personalized medicine achieved for many types of cancer, chemotherapy still represents the mainstay of treatment for PC. Olaparib was the first agent to demonstrate a significant benefit in a biomarker-selected population, opening the doors for a personalized approach. Despite the failure of a large number of studies testing targeted agents or immunotherapy to demonstrate benefits over standard chemotherapy regimens, some interesting agents, alone or in combination with other drugs, have achieved promising results. A wide spectrum of therapeutic strategies, including immune-checkpoint inhibitors tyrosine kinase inhibitors and agents targeting metabolic pathways or the tumor microenvironment, is currently under investigation. In this review, we aim to provide a comprehensive overview of the current landscape and future directions of personalized medicine for patients affected by PC.

【 授权许可】

Unknown